Astellas Pharma Inc (YPH STU) stock market data APIs
€9.0994
0(0%)
as of March 11, 2025
Astellas Pharma Inc Financial Data Overview
There is no Profile data available for YPH.SG.
Prev. Close
9.0994
Open
9.0994
High
9.0994
Low
9.0994
52 wk Range
8.68-11.39
Market Cap
25 701 M
Dividends (Yield)
1.4119
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Astellas Pharma Inc data using free add-ons & libraries
Get Astellas Pharma Inc Fundamental Data
Astellas Pharma Inc Fundamental data includes:
- Net Revenue:
- EBITDA:
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: NaN
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Astellas Pharma Inc News
New
Astellas and YASKAWA Agree to Establish a Joint Venture Focused on Cell Therapy Manufacturing
- Joint venture will aim to develop a cell therapy manufacturing platform through robotics and will offer access to startups and academic institutions - TOKYO, March 5, 2025 /PRNewswire/ -- Astellas ...
Astellas and MBC BioLabs Announce the Sixth Annual Astellas Future Innovator Prize
Awardees win a year of access to a prestigious life-science incubator in San Francisco and to Astellas expertise to further their research Award helps biotech start-ups accelerate early drug discove...
U.S. FDA Approves Expanded Label for Astellas' IZERVAY™ (avacincaptad pegol intravitreal solution) for Geographic Atrophy
IZERVAY dosing approved beyond 12 months TOKYO, Feb. 12, 2025 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced the U.S. Food and Drug Adm...
Pfizer/Astellas Tout Encouraging Data From Keytruda Combo Regime In Urothelial Cancer Showing 49% Reduction In Death Risk Vs. Chemo
On Monday, Pfizer Inc. (NYSE:PFE) and Astellas Pharma Inc. (OTC:ALPMF) (OTC:ALPMY) released additional follow-up results from the Phase 3 EV-302 trial (also known as KEYNOTE-A39) of Padcev (enfortum...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
